Multiple sclerosis (MS) is considered to be a predominantly T-cell-mediated disease, and emerging evidence indicates that dendritic cells have a critical role in the initiation and progression of ...

New Study Finds a Promising Combined Therapy for Multiple Sclerosis Oct. 2, 2024 — Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

Kesimpta is a brand-name subcutaneous injection prescribed for certain forms of multiple sclerosis (MS ... MS symptoms within 2 weeks of starting treatment. However, others experienced benefits ...

Columnist Desiree Lama describes her journey with MS-related bladder problems that were brought under control but are now ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Therefore, professionals usually reserve this treatment for cases where other multiple sclerosis treatment options, such as oral medications or physical therapy, have been ineffective. It is ...

Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals and patients with multiple sclerosis that treatment with ...

Potential autoimmune diseases therapies that target dendritic cells aim to either inhibit immunogenic dendritic cell functions or support their tolerogenic potential (Figure 2). Most strategies ...